Search results for "ddc:610"

showing 10 items of 435 documents

Comparison of genetic risk prediction models to improve prediction of coronary heart disease in two large cohorts of the MONICA/KORA study

2021

Abstract It is still unclear how genetic information, provided as single‐nucleotide polymorphisms (SNPs), can be most effectively integrated into risk prediction models for coronary heart disease (CHD) to add significant predictive value beyond clinical risk models. For the present study, a population‐based case‐cohort was used as a trainingset (451 incident cases, 1488 noncases) and an independent cohort as testset (160 incident cases, 2749 noncases). The following strategies to quantify genetic information were compared: A weighted genetic risk score including Metabochip SNPs associated with CHD in the literature (GRSMetabo); selection of the most predictive SNPs among these literature‐co…

Oncologymedicine.medical_specialtyEpidemiologyFramingham Risk Score ; Metabochip ; Coronary Heart Disease ; Genomic Risk Prediction ; Priority-lassoPopulationCoronary DiseaseSingle-nucleotide polymorphismKoronare HerzkrankheitPolymorphism Single NucleotideRisk AssessmentCohort Studies03 medical and health sciencesRisk FactorsInternal medicinemedicineHumansgenomic risk predictionddc:610coronary heart diseaseMetabochipGenetikeducationGenotypingGenetics (clinical)030304 developmental biologypriority‐Lasso0303 health scienceseducation.field_of_studyFramingham Risk ScoreModels GeneticProportional hazards modelbusiness.industry030305 genetics & heredityGenomicsConfidence intervalddc:Coronary disease; GeneticsRisk factorsCohortFramingham risk scorebusinessDDC 610 / Medicine & healthPredictive modelling
researchProduct

Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic …

2020

Purpose: We aimed to compare treatment results in and outside of a randomized trial and to confirm factors influencing outcome in a large retrospective cohort of nonmetastatic medulloblastoma treated in Austria, Switzerland and Germany. Methods and Materials: Patients with nonmetastatic medulloblastoma (n = 382) aged 4 to 21 years and primary neurosurgical resection between 2001 and 2011 were assessed. Between 2001 and 2006, 176 of these patients (46.1%) were included in the randomized HIT SIOP PNET 4 trial. From 2001 to 2011 an additional 206 patients were registered to the HIT 2000 study center and underwent the identical central review program. Three different radiation therapy protocols…

Oncologymedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentMedizinTreatment results030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicineRadiology Nuclear Medicine and imagingScientific Articleddc:610MedulloblastomaUnivariate analysisddc:618business.industryHazard ratioRetrospective cohort studymedicine.diseaseRadiation therapyOncology030220 oncology & carcinogenesisbusinessAdvances in Radiation Oncology
researchProduct

Immunotherapy: New Options in Gastrointestinal Cancers?

2019

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGastroenterologyImmunotherapyImmunotherapy Gastrointestinal CancersText miningInternal medicinemedicineSurgeryddc:610businessInterdisciplinary DiscussionVisceral Medicine
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Parent of origin effects in attention/deficit hyperactivity disorder (ADHD): analysis of data from the international multicenter ADHD genetics (IMAGE…

2008

Contains fulltext : 71540.pdf (Publisher’s version ) (Closed access) There are conflicting reports suggesting that the parental origin of transmitted risk alleles may play a role in the etiology of attention deficit/hyperactivity disorder (ADHD). A recent report by Hawi and colleagues observed a generalized paternal over-transmission of alleles associated with ADHD. This was not replicated in more recent studies. Using data from a large multicenter study we examined the overall and gene-specific parent of origin effect in 554 independent SNPs across 47 genes. Transmission disequilibrium and explicit parent of origin test were performed using PLINK. Overall parent of origin effect was tested…

ParentsCandidate geneGenetics and epigenetic pathways of disease [NCMLS 6]2804 Cellular and Molecular NeuroscienceMedizinNeuroinformatics [DCN 3]Linkage Disequilibrium2738 Psychiatry and Mental Health0302 clinical medicineRisk FactorsPerception and Action [DCN 1]Genetics(clinical)Genetics (clinical)0303 health sciencesTPH210058 Department of Child and Adolescent PsychiatryPsychiatry and Mental healthData Interpretation StatisticalFunctional Neurogenomics [DCN 2]Clinical psychologyGenetic Markers2716 Genetics (clinical)Single-nucleotide polymorphism610 Medicine & healthMental health [NCEBP 9]Polymorphism Single NucleotideGenetic determinismGenomic disorders and inherited multi-system disorders [IGMD 3]Molecular epidemiology [NCEBP 1]03 medical and health sciencesCellular and Molecular NeuroscienceCognitive neurosciences [UMCN 3.2]Translational research [ONCOL 3]medicineAttention deficit hyperactivity disorderHumansFamilyGenetic Predisposition to Diseaseddc:610Medizinische Fakultät » Universitätsklinikum Essen » LVR-Klinikum Essen » Klinik für Psychiatrie Psychosomatik und Psychotherapie des Kindes- und JugendaltersAlleleAlleles030304 developmental biologyChi-Square DistributionEndocrinology and reproduction [UMCN 5.2]business.industrymedicine.diseaseGenetic defects of metabolism [UMCN 5.1]Multicenter studyAttention Deficit Disorder with HyperactivityEtiologybusiness030217 neurology & neurosurgeryAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
researchProduct

Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression

2012

Wnt modulates glioma vascularization by regulating PDGF-B expression.

PathologyAngiogenesisCentral Nervous System NeoplasmsMice0302 clinical medicineImmunology and AllergyWnt Signaling Pathwaybeta Catenin0303 health sciencesbiologyNeovascularization PathologicBrain NeoplasmsWnt signaling pathwayIntracellular Signaling Peptides and ProteinsForkhead Transcription FactorsGliomaProto-Oncogene Proteins c-sis3. Good healthmedicine.anatomical_structureBlood-Brain Barrier030220 oncology & carcinogenesiscardiovascular systemIntercellular Signaling Peptides and ProteinsFemalemedicine.medical_specialtyBeta-cateninEndotheliumImmunologyNotch signaling pathwayMice NudeWnt1 ProteinMural cellArticle03 medical and health sciencesGliomamedicineAnimalsHumansddc:610neoplasms030304 developmental biologyAdaptor Proteins Signal TransducingCalcium-Binding ProteinsMembrane Proteinsmedicine.diseaseXenograft Model Antitumor Assaysnervous system diseasesDKK1Cancer researchbiology.proteinEndothelium VascularNeoplasm Grading
researchProduct

Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach

2013

Orthotopic bladder cancer xenografts are essential for testing novel therapies and molecular manipulations of cell lines in vivo. Current xenografts rely on tumor cell inoculation by intravesical instillation or direct injection into the bladder wall. Instillation is limited by the lack of cell lines that are tumorigenic when delivered in this manner. The invasive model inflicts morbidity on the mice by the need for laparotomy and mobilization of the bladder. Furthermore this procedure is complex and time-consuming. Three bladder cancer cell lines (UM-UC1, UM-UC3, UM-UC13) were inoculated into 50 athymic nude mice by percutaneous injection under ultrasound guidance. PBS was first injected b…

PathologyMouseTumor PhysiologyCancer Treatmentlcsh:MedicineMiceBasic Cancer ResearchMedicineUltrasonicslcsh:ScienceBladder Cancer and Urothelial Neoplasias of the Urinary TractMultidisciplinaryUltrasoundAnimal ModelsBladder CancerOncolytic VirusesOncologySurgery Computer-AssistedMedicineOncology AgentsFemaleImmunotherapyResearch Articlemedicine.drugmedicine.medical_specialtyClinical Research DesignUrologyTransplantation HeterologousModel OrganismsIn vivoCell Line TumorAnimalsHumansBioluminescence imagingddc:610Animal Models of DiseaseBiologyCell ProliferationCisplatinBladder cancerbusiness.industrylcsh:RCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseaseGemcitabineOncolytic virusTransplantationGenitourinary Tract TumorsUrinary Bladder NeoplasmsFeasibility Studieslcsh:QbusinessPLoS ONE
researchProduct

MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer’s Disease

2012

Imaging markers of early neurodegeneration play an important role for the definition of predementia and preclinical stages of Alzheimer’s disease according to the newly proposed diagnostic consensus c

Pathologymedicine.medical_specialtybusiness.industryNeurodegenerationmedicineddc:610Diseasemedicine.diseasebusinessNeuroscience
researchProduct

Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model

2015

Breakdown of the blood-brain barrier (BBB) is an early hallmark of multiple sclerosis (MS), a progressive inflammatory disease of the central nervous system. Cell adhesion in the BBB is modulated by sphingosine-1-phosphate (S1P), a signaling protein, via S1P receptors (S1P\(_1\)). Fingolimod phosphate (FTY720-P) a functional S1P\(_1\) antagonist has been shown to improve the relapse rate in relapsing-remitting MS by preventing the egress of lymphocytes from lymph nodes. However, its role in modulating BBB permeabilityin particular, on the tight junction proteins occludin, claudin 5 and ZO-1has not been well elucidated to date. In the present study, FTY720-P did not change the transendotheli…

Pathologytight junctionsDrug Evaluation PreclinicalApoptosisVascular permeabilityOccludinlcsh:ChemistryMedicinelcsh:QH301-705.5Cells CulturedSpectroscopyTight junctionrat brain microvascular endothelial cell cultureGeneral MedicineFingolimodComputer Science ApplicationsCell biologyEndothelial stem cellmedicine.anatomical_structureMatrix Metalloproteinase 2Immunosuppressive AgentsFTY720-P; blood-brain barrier; rat brain microvascular endothelial cell culture; inflammation; tight junctionsmedicine.drugmedicine.medical_specialtyMultiple SclerosisMAP Kinase Signaling SystemBlood–brain barrierArticleCatalysisCapillary PermeabilityInorganic ChemistryOccludinFingolimod HydrochlorideAnimalsFTY720-Pddc:610Physical and Theoretical ChemistryClaudinMolecular BiologyFingolimod Hydrochloridebusiness.industryOrganic ChemistryEndothelial Cellsblood-brain barrierRatslcsh:Biology (General)lcsh:QD1-999inflammationMicrovesselsbusinessInternational Journal of Molecular Sciences
researchProduct

A Prevalence Estimation of Exstrophy and Epispadias in Germany From Public Health Insurance Data

2021

Introduction: The prevalence of rare diseases is very important for health care research. According to the European Surveillance of Congenital Anomalies (EUROCAT) registers, the live prevalence for exstrophy and/or epispadias (grades 1–3) is reported with 1:23,255 (95% CI: 1:26,316; 1:20,000). A Europe-wide prevalence evaluation based on reports from excellence centers estimates a prevalence for exstrophies of 1:32,200 and for isolated epispadias of 1:96,800 in 2010. However, the frequency of exstrophy [International Statistical Classification of Diseases and Related Health Problems revision 10 (ICD-10): Q64.1] and epispadias (ICD-10: Q64.0) treated in different age groups in Germany remain…

Pediatricsmedicine.medical_specialtyEpispadiasKrankenversicherungprevalencePopulationSubgroup analysisEpispadiasPediatricsRJ1-570BlasenekstrophieBladder exstrophy epispadias complex (EEC)Bladder exstrophyepispadiasHealth carePrevalencebladder exstrophy epispadias complex (EEC)International Statistical Classification of Diseases and Related Health ProblemsMedicineddc:610educationEpispadieOriginal ResearchPublic healtheducation.field_of_studyInsurance Healthbusiness.industryIncidence (epidemiology)Public healthpublic healthmedicine.diseaseRare diseasesBladder exstrophyhealth insurancePediatrics Perinatology and Child Healthbusinessbladder exstrophyFrontiers in Pediatrics
researchProduct